Methotrexate Use in Sjögren's Syndrome

Introduction to Methotrexate Efficacy

The European League Against Rheumatism (EULAR) guidelines state that there is insufficient evidence to recommend one immunosuppressive agent over another in Sjögren's syndrome, including methotrexate, due to lack of head-to-head studies and unacceptable adverse event rates (41-100%) in available trials 1
Methotrexate has limited evidence for efficacy in primary Sjögren's syndrome and is not recommended as a standard treatment for sicca symptoms or systemic disease, though it may be considered for specific extraglandular manifestations such as cutaneous vasculitis or as a steroid-sparing agent in select cases of systemic involvement 1

In patients with active systemic disease requiring long-term corticosteroids, methotrexate may be used as a glucocorticoid-sparing agent, though this is based on extrapolation rather than direct evidence 1
The decision to use methotrexate as a steroid-sparing agent must weigh potential benefits against risks on a case-by-case basis 1

Methotrexate is specifically listed as a medication that can cause drug-induced interstitial lung disease (ILD) in Sjögren's patients, which is a critical consideration given that Sjögren's patients may already have underlying pulmonary involvement 2, 3, 4
Clinicians must maintain high vigilance for pulmonary complications when using methotrexate in Sjögren's syndrome 2, 3, 4

Mycophenolate mofetil (MMF) or azathioprine are recommended as first-line steroid-sparing or adjunct agents for Sjögren's-related interstitial lung disease 2, 3, 4
Rituximab should be considered for severe, refractory systemic disease, as it has the highest level of evidence among biologics tested in Sjögren's syndrome (>400 patients studied) 1
Cyclophosphamide or rituximab are preferred for rapidly progressive or life-threatening manifestations 2, 3, 4